Q32 Bio Inc. (QTTB)
Q32 Bio, Inc. operates as a clinical stage biotechnology company developing biologic therapeutics targeting potent regulators of the innate and adaptive immune systems to re-balance immunity in autoimmune and inflammatory diseases. It focuses on the IL-7 / TSLP receptor pathways and complement system, addressing immune dysregulation to help patients take back control of their lives. The company was founded by David Grayzel and Shelia Violette in 2017 and is headquartered in Waltham, MA.
Address
830 WINTER STREET
WALTHAM, MA 02451
Founded
2017
Number of Employees
7
Website
http://www.q32bio.com
Insider Transactions
Filters
Keyboard Shortcuts: Show (a) | Close (Esc)